CancerDrs

Brain Cancer clinical trials in Utah

22 actively recruiting brain cancer trials at 2 sites across Utah.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Utah:
  • University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2, Phase 3 Recruiting Academic/Other

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …

Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Utah:
  • University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…

Sponsor: CarThera
NCT ID: NCT05902169
Sites in Utah:
  • University of Utah, Hunstman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other

Combination Therapy for the Treatment of Diffuse Midline Gliomas

This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…

Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Utah:
  • University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Utah:
  • University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Industry

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …

Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Utah:
  • University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Academic/Other

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combin…

Sponsor: University of Utah
NCT ID: NCT06194929
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combi…

Sponsor: Orbus Therapeutics, Inc.
NCT ID: NCT05879367
Sites in Utah:
  • University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Academic/Other

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received ra…

Sponsor: University of Utah
NCT ID: NCT02390518
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
NA Recruiting Academic/Other

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Utah:
  • George E. Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
NA Recruiting Academic/Other

Guided Meditation During Radiation Therapy for Brain Tumors

The goal of this interventional treatment study is to assess the anxiolytic effect of providing guided meditation during radiation treatment (RT) in patients with brain tumors. The main question it aims to answer is: • What is the change i…

Sponsor: University of Utah
NCT ID: NCT06165653
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07